Inside the body with Eloralintide

Lys26 is acylated (gamma-Glu-gamma-Glu-C20 diacid) to bind albumin. In people with obesity, absorption after subcutaneous dosing is slow, the half-life is about 14 days, exposure is dose-proportional, and steady-state peak-to-trough ratios are 1.28 to 1.38. The authors suggest this flat profile may help gastrointestinal tolerability (an indirect inference, not a tested result).[src][src]

Amylin receptors are heterodimers of the calcitonin receptor with RAMP1 (AMY1R) or RAMP3 (AMY3R). In cell-line cAMP assays eloralintide was about 12-fold more potent at human AMY1R (EC50 23.9 pM) than at the human calcitonin receptor and about 11-fold more potent than at human AMY3R; in rat receptors both AMY1R and AMY3R were activated more potently than the calcitonin receptor. This is receptor pharmacology in cells. Where in the human brain it acts has not been shown for eloralintide; a mouse study of the related agonist cagrilintide found its weight-lowering effect depended on RAMP1/RAMP3 and activated hindbrain neurons (animal-only evidence for a different molecule).[src][src]

Native amylin promotes meal termination through central mechanisms. Lilly states the effects of eloralintide are likely mediated by affecting satiety. In the multiple-ascending-dose study, decreased appetite was the most common adverse event (19% of eloralintide-treated participants), and fasting appetite scores showed only a non-significant trend toward lower appetite. The mechanism is inferred from receptor pharmacology, animal data and the class; none of the sources cited here measured satiety pathways directly in people.[src][src][src]

Class physiology: amylin is co-secreted with insulin from pancreatic beta cells, slows gastric emptying and suppresses glucagon secretion (review). For eloralintide itself, the 12-week phase 1 multiple-ascending-dose study used acetaminophen absorption as a gastric-emptying marker: higher doses modestly lowered acetaminophen exposure after the first dose, exposure returned toward baseline by Day 80, and acetaminophen tmax did not differ significantly from placebo. The authors say any gastric-emptying effect may be transient and that this needs confirmation. Fasting glucagon decreased non-significantly without a consistent dose relationship, and fasting glucose was essentially unchanged in this normoglycaemic population. In the phase 2 trial Lilly reported improved glycemic control measures in participants without type 2 diabetes.[src][src][src]

Animal-only evidence: in diet-induced obese rats given repeated doses, eloralintide dose-dependently reduced food intake and body weight, and fat mass accounted for about 85%, 77% and 68% of the weight lost across three increasing dose levels. In lean rats, eloralintide produced less conditioned taste avoidance than cagrilintide at a similar 24-hour food-intake reduction (p < 0.05), a proxy for aversion. Body-composition results in humans from the phase 2 trial are not reported in the cited abstract.[src]

Phase 2 (n = 263, adults with obesity or overweight without type 2 diabetes): mean percent change in body weight at 48 weeks (efficacy estimand) ranged from -9.5% to -20.1% across arms versus -0.4% on placebo (Lilly press release; Lancet abstract reports rounded values with confidence intervals). Waist circumference also improved. These are company-funded results, not adjusted for multiplicity in Lilly's summary.[src][src]

Lilly reports that eloralintide was associated with improvements in waist circumference, blood pressure, lipid profiles, glycemic control and markers of inflammation in the phase 2 trial; the release gives no figures for these outcomes. No cardiovascular outcomes trial of eloralintide has reported; effects on hard cardiovascular events are unknown.[src]